ABSTRACT
Over the course of the last decade, considerable strides have been made in the treatment of human immunodeficiency virus (HIV) infection, with resultant reductions in mortality and morbidity (1). Similarly, the clinical manifestations of HIV infection have changed dramatically over this period. The presenting signs and symptoms of immunodeficiency and associated opportunistic infections have been largely replaced by organ-specific involvement, such as nephropathy. More recently, as viral loads have been reduced, these clinical manifestations have further evolved to include adverse effects associated with antiretroviral agents, and cardiomyopathy has become increasingly recognized as clinical sequela of chronic retroviral infection.
